Yahoo Finance

Viral Vector Collaboration and Licensing Agreements Analysis Report and Directory 2016-2025: Access to Confidential Contract Documents for In-Depth Due Diligence and Benchmarking

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...
Yahoo Finance

Viral Vector Collaboration and Licensing Agreements Analysis Report 2024 with Directory of 396 Deals Signed Since 2016 by Company A-Z, Financial terms, Deal Type and Therapy Focus

Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. This report contains a ...
Finanznachrichten

VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

~ Agreement grants VectorY the exclusive right to evaluate and license Shape's non-invasive, deep-brain penetrating AAV5-derived capsid for vectorized antibodies against three targets ~ ~ License will ...
Reuters

I'rom Group unit ID Pharma concludes licensing agreement on Sendai Virus Vector technology with U.S.-based Elixirgen

* Says unit ID Pharma Co., Ltd. grants Elixirgen non-exclusive rights to use Sendai Virus Vector technology to make products with Elixirgen's genes for research purpose and rights to sell the products ...
Reuters

Bluebird Bio entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma

* Bluebird bio inc- financial terms of agreement with novartis include an upfront payment to bluebird as well as milestone and royalty payments * Bluebird bio-under terms novartis to non-exclusively ...
WGNO

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular ...
Pharm Exec

VectorY Therapeutics Enters Option and License Agreement with Shape Therapeutics for SHP-DB1

VectorY gains exclusive rights to evaluate and potentially license SHP-DB1, enhancing its neurodegenerative disease therapy pipeline. SHP-DB1, an engineered AAV5 capsid, offers improved brain ...
Mena FN

Viral Vector Collaboration And Licensing Agreements Analysis Report And Directory 2016-2025: Access To Confidential Contract Documents For In-Depth Due Diligence And Benchmarking

(MENAFN- GlobeNewsWire - Nasdaq) Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the world's ...